Literature DB >> 9792847

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.

M L De Bruijn1, H L Greenstone, H Vermeulen, C J Melief, D R Lowy, J T Schiller, W M Kast.   

Abstract

A single injection of HPV16 L1 virus-like particles induced potent CD8-mediated protection from tumor challenge by C3 cells, a line derived from embryonic mouse cells transfected with the HPV16 genome. L1 RNA, but not protein, was detected biochemically in C3 cells. These results indicate that low-level expression of HPV16 L1 can occur in proliferating cells and serve as a tumor vaccine target. Although L1 expression is generally thought to be restricted to terminally differentiated epithelial cells, these results suggest that additional analysis for low-level L1 expression in proliferating cells of HPV-induced lesions is warranted and might help in predicting the clinical potential of HPV L1 virus-like particle-based vaccines. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792847     DOI: 10.1006/viro.1998.9372

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study.

Authors:  T Kohl; I I Hitzeroth; D Stewart; A Varsani; V A Govan; N D Christensen; A-L Williamson; E P Rybicki
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 2.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

3.  Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Authors:  Hee-Jung Lee; Jong Kwang Yoon; Yoonki Heo; Hansam Cho; Yeondong Cho; Yongdae Gwon; Kang Chang Kim; Jiwon Choi; Jae Sung Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

4.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Authors:  Michael G Berg; Robert J Adams; Ratish Gambhira; Mark C Siracusa; Alan L Scott; Richard B S Roden; Gary Ketner
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

6.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

Review 7.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

8.  Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

Authors:  Rongcun Yang; Francisco Martinez Murillo; Hengmi Cui; Richard Blosser; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Authors:  Hakim Echchannaoui; Matteo Bianchi; David Baud; Martine Bobst; Jean-Christophe Stehle; Denise Nardelli-Haefliger
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.